Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRZN vs ICCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–2 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: SRZN 2 – 4 ICCC Matrix Metrics: SRZN 2 – 7 ICCC

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin).

  • Growth vs. Quality Trade-Off: ICCC earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. SRZN 34.3/100 SELL) and 0.24β · 46% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs ICCC
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $29.51 · SMA50: $26.10
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 4 ICCC)

Columns: Metric · SRZN · ICCC
1. Valuation Multiples ICCC
Forward P/E N/M N/M
Trailing P/E N/M 56.6x
PEG Ratio N/M N/M
EV / Revenue 48.3x 1.6x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +11.5%
Earnings Growth (YoY) -37.0% +259.9%
TTM Revenue (USD) $11M $67M
Market Cap $602.5M $97.7M
3. Profitability & Quality ICCC
Gross Margin N/A 40.3%
Operating Margin -485.4% 15.2%
Net Profit Margin 0.0% 2.6%
Return on Equity (ROE) -62.8% 2.6%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) -$31M $7.4M
Cash Flow Margin N/A 11.0%
Net Cash / Leverage $95M Net Cash $13M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ICCC
OpEx & R&D Intensity N/A 25.1% of Rev ($17M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (2) vs ICCC (7)
Institutional Metric SRZN ICCC Criterion Row Edge
Market Capitalization
Scale
$602.5M $97.7M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 56.6x Lower Multiple ICCC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% +11.5% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 15.2% Higher Margin ICCC
Net Profit Margin
Profitability
0.0% 2.6% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
-62.8% 2.6% Higher ROE ICCC
52-Week Range Position
Momentum
79% ($12–$38) 91% ($5–$12) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
1.21β · 62% Vol 0.24β · 46% Vol Lower Realized Risk ICCC
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite ICCC
Trailing 12M Revenue (USD)
Operating Scale
$11M $67M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 40.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) $7.4M ($13M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +31.65 pp
SRZN: +37.88% · ICCC: +6.23%
3M Horizon SRZN +17.66 pp
SRZN: +34.67% · ICCC: +17.01%
6M Horizon SRZN +2.54 pp
SRZN: +17.78% · ICCC: +15.24%
1Y Horizon SRZN +77.91 pp
SRZN: +166.67% · ICCC: +88.76%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue ICCC Revenue SRZN Op. Margin ICCC Op. Margin Margin Leader
FY2018 N/A $10M N/A -13.2% ICCC
FY2019 N/A $10M N/A -7.0% ICCC
FY2020 N/A $20M N/A -9.0% ICCC
FY2021 N/A $20M N/A 1.3% ICCC
FY2022 $10M $20M -354.7% -12.4% ICCC
FY2023 N/A $20M N/A -32.9% ICCC
FY2024 $10M $30M -239.7% -6.2% ICCC
FY2025 $0M $30M -1210.6% 6.0% ICCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs ICCC Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin). Growth vs. Quality Trade-Off: ICCC earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. SRZN 34.3/100 SELL) and 0.24β · 46% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with ICCC at +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRZN cumulative revenue shifted +0.0% while ICCC shifted +200.0%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($17M) (0 disclosures) for ICCC.

ICCC screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus ICCC (2.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.